ELANElanco Animal Health Incorporated
Is it safe?
Forensics clean, with a caveat: clean books and insiders buying, but big price swings.
Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).
Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.
Multiple insiders bought with their own money (net +$1.4M, 90 days to Oct 22, 2026).
Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -78% · now 16% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can ELAN take a bad year?
Elanco Animal Health Incorporated carries $3.39B of net debt as at Q2 2026.
Net debt · as at Q2 2026 · debt less the cash on hand
- Debt / equity
- 0.59×
Debt / equity
- Annualised volatility
- 47%
Annualised volatility · S&P 500 16% · about 3 times the market's own swing
- Worst drawdown on file
- −78%
Worst drawdown on file · −16% today
Details›
- Total debtQ2 2026
- $3.92B
- Cash and short-term investments
- $530M
- Net debt
- $3.39B
- Debt / equity
- 0.59×
- Annualised volatilitytwo years of daily moves
- 47%
- Worst drawdown on file
- −78%
- Below its 52-week high
- 16%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
The balance sheet
What it owes against what it owns, and how close that comes to trouble.
How far can it fall?
How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.
Drug Manufacturers, Specialty & Generic
Ranks #19 of 39 by RyuScore